Tempus to Acquire Personalis for $1.5 Billion

Tempus agreed to acquire Personalis for $1.5 billion, combining Personalis's MRD technology with Tempus's AI platform to expand cancer monitoring capabilities. The deal targets the $20 billion market for residual disease tracking.